Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Learn where to invest small amounts of money to achieve the best results. Make informed decisions for your financial growth.
16,784 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
A tight group of U.S.-listed power chip stocks built around silicon carbide and GaN technologies are rallying as elec...
Amazon's AI hardware strategy could extend far beyond cloud services. This article explains how Trainium and Inferent...
With federal Medicaid work requirements looming, several states are pushing legislation to publicly name big employer...
Aehr Test Systems faces a pivotal Q4 print after the market closes, with AI burn-in demand and bookings in focus as t...
A Cytokinetics insider sale coincides with a stunning stock move. This article breaks down what the trade might signa...
An unusual trading day put Lucid Group in the spotlight after rumors swirled about bankruptcy or going private. Learn...
American Airlines is set to report July earnings, and investors will scrutinize demand signals, guidance, and cost tr...
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Could Amazon hit a $4 trillion market value by 2027? This guide breaks down the odds, drivers, and actionable moves f...
As AI partnerships captivate the market, UiPath shares edged higher amid broader tech weakness. This look at stock ma...
Copart director Daniel Englander recently sold 80,000 shares for about $2.2 million. With CPRT down roughly 40%, inve...